NLRP12/NLRC4 knockdown, GSDMD knockout, or the neutralization of mature IL-33 can obviously attenuate the damage to corneal epithelial cells, indicating that these molecules could be key targets for dry eye treatment in the future (Chen et al., 2020b). This evidence concerns the gene NLRC4 and dry eye syndrome.